Antibacterial and antifungal pyrazoles based on different construction strategies
- PMID: 39608204
- DOI: 10.1016/j.ejmech.2024.117081
Antibacterial and antifungal pyrazoles based on different construction strategies
Erratum in
-
Corrigendum to "Antibacterial and antifungal pyrazoles based on different construction strategies" [Euro. J. Med. Chem. 282 (2025) 117081].Eur J Med Chem. 2025 Feb 5;283:117147. doi: 10.1016/j.ejmech.2024.117147. Epub 2024 Dec 10. Eur J Med Chem. 2025. PMID: 39665967 No abstract available.
Abstract
The growing prevalence of microbial infections, and antimicrobial resistance (AMR) stemming from the overuse and misuse of antibiotics, call for novel therapeutic agents, particularly ones targeting resistant microbial strains. Scientists are striving to develop innovative agents to tackle the rising microbial infections and abate the risk of AMR. Pyrazole, a five-membered heterocyclic compound belonging to the azole family, is a versatile scaffold and serves as a core structure in many drugs with antimicrobial and other therapeutic effects. In this review, we have updated pyrazole-based antibacterial and antifungal agents mainly developed between 2016 and 2024, by combining with diverse pharmacophores such as coumarin, thiazole, oxadiazole, isoxazole, indole, etc. Meanwhile, the various strategies (molecular hybridization, bioisosterism, scaffold hopping, multicomponent reactions, and catalyst-free synthesis) for integrating different functional groups with the pyrazole ring are discussed. Additionally, structure-activity relationships of these pyrazole derivatives, i.e., how structural modifications impact their selectivity and therapeutic potential against bacterial and fungal strains, are highlighted. This review provides insights into designing next-generation antimicrobials to combat AMR, and offers valuable perspectives to the scientists working on heterocyclic compounds with diverse bioactivities.
Keywords: Antibacterial agents; Antifungal agents; Antimicrobial resistance; Construction strategies; Pharmacophores; Pyrazole; Structure-activity relationship.
Copyright © 2024 Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous